Zynerba Pharmaceuticals has launched a pivotal Phase 3 clinical trial, called CONNECT-FX, that will assess the safety and effectiveness of its cannabis-based ZYN002 as a potential therapy to treat behavioral symptoms in patients with fragile X syndrome. Top-line results from the trial are expected in…
News
Aripiprazole Improved Irritable Behavior in Patients With Fragile X Syndrome, Phase 2 Study Shows
Irritable behavior in patients with fragile X syndrome significantly improved after receiving aripiprazole, an antipsychotic medication previously approved by the U.S. Food and Drug Administration (FDA) to treat other psychotic conditions. The study, “A prospective open-label of aripiprazole in fragile X syndrome,” was published in Psychopharmacology. Fragile…
Invitae Corporation has launched the Invitae Carrier Screen, an affordable test designed to inform prospective parents of genetic changes that increase their risk of having a child with an inherited genetic disorder, such as fragile X syndrome. “By providing affordable, comprehensive, high-quality genetic information, Invitae carrier testing can help parents-to-be…
Chemical modification of a DNA-binding protein may provide a new therapeutic target to treat fragile X syndrome (FXS), a mouse study suggests. The study, “Reducing histone acetylation rescues cognitive deficits in a mouse model of Fragile X syndrome,” was published in …
A gene editing tool based on gold nanoparticles called CRISPR-Gold was able to reduce the repetitive behaviors associated with autism spectrum disorders (ASD) in a mouse model of fragile X syndrome (FXS), a recent study shows. The study, “Nanoparticle delivery of CRISPR into the brain rescues…
Researchers have identified a possible biomarker to detect fragile X-associated tremor/ataxia syndrome (FXTAS), according to case report. The study, “In tracellular FMRpolyG-HSP70 complex: Possible use as biochemical marker of Fragile X Tremor Ataxia Syndrome,” was published in bioRxiv. FXTAS is a late-onset neurodegenerative disease that affects those who…
Social-environmental variables can influence self-injury behavior in a large proportion of boys with fragile X syndrome, according to researchers. Their study, “Examining the influence of social-environmental variables on self-injurious behaviour in adolescent boys with fragile X syndrome,” was published in the Journal of Intellectual Disability Research.
Patients with fragile X syndrome who don’t meet the cut-off for a diagnosis of autism show a decrease in impulsivity and repetitive questioning over time, when compared with patients who do, a new study shows. The study, “Overactivity, impulsivity and repetitive behaviour in males with fragile X syndrome: contrasting…
Children with fragile X syndrome exhibit abnormal gesture use (a form of non-verbal communication) early in development, partially accounting for autism spectrum disorder (ASD) symptom severity, according to a recent study. The study “Early gesture use in fragile X syndrome” was published in the Journal of Intellectual Disability Research.
Scientists have developed a new technique for genetic testing that can predict a woman’s risk of having a child with fragile X syndrome when she carries a specific type of mutation. The study that discusses the method, “Detecting AGG Interruptions in Females With a FMR1 Premutation by Long-Read Single-Molecule…
Recent Posts
- Marvel planning trial to test fragile X treatment in healthy volunteers
- FRAXA backs upcoming Phase 2b trial of SPG601 for fragile X syndrome
- Daily use of diabetes drug metformin eases hyperactivity in fragile X boys
- USC researchers net $6.3M federal grant to study fragile X mutations
- 1st patient enrolled in Phase 2 trial of treatment for fragile X syndrome
- Phase 2 trial of experimental oral treatment enrolling fragile X males
- SPG601 calms brain activity in men with fragile X, helping them to focus
- Cannabidiol gel ZYN002 for fragile X fails to meet goal in clinical trial
- Fragile X, ASD children have distinct brain network patterns
- SPG601 granted orphan drug status in EU for treating fragile X